A provider briefing on Bimatoprost availability in 2026. Shortage timeline, prescribing implications, cost and access challenges, and tools to help patients.
As clinicians managing patients with open-angle glaucoma and ocular hypertension, reliable access to first-line prostaglandin analogs is essential to treatment continuity. Over the past 12-18 months, intermittent supply disruptions for Bimatoprost (brand: Lumigan) have created challenges for both prescribers and patients — leading to missed doses, unplanned medication switches, and patient frustration.
This briefing summarizes the current Bimatoprost availability landscape, its prescribing implications, and practical steps your practice can take to minimize treatment interruptions for your patients.
Understanding the supply timeline helps contextualize the current situation:
The supply constraints carry several clinical considerations for prescribers:
Bimatoprost is available in two ophthalmic concentrations: 0.01% and 0.03%. The 0.01% concentration — which became the standard Lumigan formulation due to reduced conjunctival hyperemia — has been the more difficult-to-source strength. The 0.03% concentration, while primarily associated with Latisse for cosmetic use, is also used for IOP reduction and has generally been more available.
When prescribing, consider specifying whether the patient can accept either concentration, or discuss with the pharmacy whether substitution is appropriate under your state's pharmacy practice regulations.
Multiple generic manufacturers now produce Bimatoprost ophthalmic solution. Generic formulations are therapeutically equivalent (AB-rated) to the branded product. However, patients may notice differences in dropper design, preservative systems, or subjective comfort between manufacturers. If a patient reports new side effects or efficacy changes after a manufacturer switch, consider this as a potential factor.
Several commercial and Medicare Part D plans have repositioned Bimatoprost on their formularies in recent years. Common changes include:
These formulary shifts can delay access even when pharmacy supply is adequate. Proactive prior authorization and documentation of clinical rationale (e.g., Latanoprost intolerance, insufficient IOP reduction) can help navigate these requirements.
As of March 2026:
Cost remains a significant barrier for many glaucoma patients, particularly the uninsured and underinsured:
For patients experiencing cost barriers, consider directing them to the AbbVie At Your Service co-pay savings program (up to $2,640/year for Lumigan) or the Allergan Patient Assistance Program (PAP) for eligible uninsured patients. Discount card programs like GoodRx and SingleCare can also significantly reduce generic costs. A detailed patient resource is available at our Bimatoprost savings guide.
Several tools can help your practice and patients navigate availability challenges:
Medfinder allows providers and patients to check real-time pharmacy availability for Bimatoprost and other medications. You can direct patients to the platform or use it within your practice to identify pharmacies with current stock before sending prescriptions.
When Bimatoprost is unavailable, the following alternatives are therapeutically appropriate for most patients:
For a patient-facing resource, see alternatives to Bimatoprost.
For appropriate candidates, the Durysta intracameral implant eliminates pharmacy-level availability concerns entirely. The implant is procured through buy-and-bill or specialty distribution channels, giving your practice direct control over supply. It's particularly valuable for patients with adherence challenges or chronic difficulty obtaining drops.
The Bimatoprost supply landscape is gradually improving. The entry of new generic manufacturers, particularly for the 0.01% concentration, should continue to ease availability throughout 2026. However, the broader trend of ophthalmic drug supply constraints — driven by the limited number of sterile manufacturing facilities — is likely to persist as an industry-wide challenge.
Practices that proactively establish relationships with multiple pharmacies, maintain awareness of formulary changes, and educate patients on navigation tools like Medfinder will be best positioned to minimize treatment disruptions.
Bimatoprost remains an effective and important prostaglandin analog for IOP reduction. While supply challenges have been frustrating for providers and patients alike, the situation is improving. By staying informed about availability trends, leveraging real-time pharmacy search tools, and having a clear alternative medication strategy, your practice can help ensure that supply disruptions don't translate into gaps in glaucoma care.
For additional provider resources, including a step-by-step guide for helping patients find Bimatoprost, see our companion article: How to Help Your Patients Find Bimatoprost in Stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
